HRP20040550A2 - 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines and piperazines - Google Patents
3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines and piperazinesInfo
- Publication number
- HRP20040550A2 HRP20040550A2 HR20040550A HRP20040550A HRP20040550A2 HR P20040550 A2 HRP20040550 A2 HR P20040550A2 HR 20040550 A HR20040550 A HR 20040550A HR P20040550 A HRP20040550 A HR P20040550A HR P20040550 A2 HRP20040550 A2 HR P20040550A2
- Authority
- HR
- Croatia
- Prior art keywords
- disubstituted
- piperazines
- alzheimer
- amyloid
- substituted piperidines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33270801P | 2001-11-19 | 2001-11-19 | |
| US38316702P | 2002-05-24 | 2002-05-24 | |
| PCT/US2002/037037 WO2003043987A2 (en) | 2001-11-19 | 2002-11-19 | (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20040550A2 true HRP20040550A2 (en) | 2006-11-30 |
Family
ID=26988352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040550A HRP20040550A2 (en) | 2001-11-19 | 2004-06-16 | 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines and piperazines |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7338965B2 (ru) |
| EP (1) | EP1448200A2 (ru) |
| JP (1) | JP2005514362A (ru) |
| KR (1) | KR20050044533A (ru) |
| AP (1) | AP2004003052A0 (ru) |
| AU (1) | AU2002360403A1 (ru) |
| BR (1) | BR0214295A (ru) |
| CA (1) | CA2467749A1 (ru) |
| CO (1) | CO5580743A2 (ru) |
| EA (1) | EA200400699A1 (ru) |
| GE (1) | GEP20074045B (ru) |
| HR (1) | HRP20040550A2 (ru) |
| IL (1) | IL162079A0 (ru) |
| IS (1) | IS7271A (ru) |
| MX (1) | MXPA04004772A (ru) |
| NO (1) | NO20042580L (ru) |
| NZ (1) | NZ533158A (ru) |
| OA (1) | OA12812A (ru) |
| RS (1) | RS54204A (ru) |
| TN (1) | TNSN04088A1 (ru) |
| WO (1) | WO2003043987A2 (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CA2604291A1 (en) | 2005-04-08 | 2006-10-19 | Comentis, Inc. | Compounds which inhibit beta-secretase activity and methods of use thereof |
| EP1816122A3 (en) * | 2006-01-19 | 2007-09-19 | Speedel Experimenta AG | 3,4,5-substituted piperidines as therapeutic compounds |
| WO2007147265A1 (en) | 2006-06-23 | 2007-12-27 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| KR100679869B1 (ko) * | 2006-10-27 | 2007-02-07 | 한국기계연구원 | Ｄｐｆ시스템용 플라즈마 반응기와 이를 이용한 입자상물질의 저감 장치 |
| CA2664130A1 (en) | 2006-09-21 | 2008-03-27 | Merck & Co., Inc. | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| KR100838645B1 (ko) * | 2006-09-28 | 2008-06-16 | 한국화학연구원 | 베타-세크리테아제 활성을 억제하는 피페리딘 화합물 |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| KR100894713B1 (ko) * | 2007-10-08 | 2009-04-24 | 한국화학연구원 | 베타-세크리테아제의 활성을 저해하는 아릴피페라진이 치환된 피페리딘 유도체 또는 이의 약제학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 신경퇴행성 질환의 예방 또는 치료용 조성물 |
| EP3130674B1 (en) | 2008-11-03 | 2020-07-08 | ADC Therapeutics SA | Antibodies that specifically block the biological activity of a tumor antigen |
| ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
| EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| EA022420B1 (ru) | 2010-03-10 | 2015-12-30 | Пробиодруг Аг | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| EP3173427B1 (en) | 2011-03-31 | 2019-06-19 | ADC Therapeutics SA | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
| EP3533468A1 (en) | 2012-01-09 | 2019-09-04 | ADC Therapeutics SA | Method for treating breast cancer |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3992441A (en) * | 1972-12-26 | 1976-11-16 | Pfizer Inc. | Sulfamylbenzoic acids |
| US4248876A (en) * | 1977-01-08 | 1981-02-03 | John Wyeth & Brother Ltd. | Piperidine derivatives |
| US5142056A (en) * | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| GB8430581D0 (en) * | 1984-12-04 | 1985-01-09 | Ferrosan As | Treatment |
| DE3640475A1 (de) * | 1986-11-27 | 1988-06-09 | Hoechst Sa Lab | Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung |
| GB8714789D0 (en) * | 1987-06-24 | 1987-07-29 | Lundbeck & Co As H | Heterocyclic compounds |
| IE63906B1 (en) * | 1987-11-13 | 1995-06-14 | Novo Nordisk As | Azabicyclic compounds and their preparation and use |
| US4997836A (en) * | 1988-11-11 | 1991-03-05 | Takeda Chemical Industries, Ltd. | Trisubstituted piperazine compounds, their production and use |
| US5708004A (en) * | 1990-11-19 | 1998-01-13 | Monsanto Company | Retroviral protease inhibitors |
| ES2123065T3 (es) * | 1992-08-25 | 1999-01-01 | Searle & Co | Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas. |
| US5475138A (en) * | 1994-07-07 | 1995-12-12 | Pharm-Eco Laboratories Incorporated | Method preparing amino acid-derived diaminopropanols |
| PT863875E (pt) * | 1995-09-07 | 2003-10-31 | Hoffmann La Roche | Novos compostos 4-(oxialcoxifenil)-3-oxi-piperidina para o tratamento de insuficiencia cardiaca e renal |
| WO1998033795A1 (en) | 1997-02-04 | 1998-08-06 | The Regents Of The University Of California | Nanomolar, non-peptide inhibitors of cathepsin d |
| WO1999012532A2 (en) | 1997-09-08 | 1999-03-18 | F.Hoffmann-La Roche Ag | Piperidine derivatives against malaria |
| CN1173972C (zh) * | 1997-11-05 | 2004-11-03 | 神经研究公司 | 氮杂环醚衍生物及其作为烟碱乙酰胆碱受体调节剂的应用 |
| HUP0101320A3 (en) * | 1998-01-21 | 2002-11-28 | Kyowa Hakko Kogyo Kk | Benzo- and pyridobenzoxepine and -benzazepine derivatives and use thereof |
| GB9810671D0 (en) * | 1998-05-18 | 1998-07-15 | Pfizer Ltd | Anti-pruritic agents |
| EP1097137A1 (en) * | 1998-07-10 | 2001-05-09 | AstraZeneca AB | N-substituted naphthalene carboxamides as neurokinin-receptor antagonists |
| US6274735B1 (en) * | 1998-08-10 | 2001-08-14 | Hoffmann-La Roche Inc. | Process and intermediates for preparation of substituted piperidines |
| AU769260B2 (en) * | 1998-10-07 | 2004-01-22 | Georgetown University | Monomeric and dimeric heterocycles, and therapeutic uses thereof |
| GB9904786D0 (en) * | 1999-03-02 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| CA2438318A1 (en) * | 2001-02-16 | 2002-08-29 | Aventis Pharmaceuticals Inc. | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands |
| US20060079533A1 (en) | 2001-03-23 | 2006-04-13 | Nieman James A | Methods of treating alzheimer's disease |
| US20030095958A1 (en) * | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
-
2002
- 2002-11-19 MX MXPA04004772A patent/MXPA04004772A/es not_active Application Discontinuation
- 2002-11-19 AP APAP/P/2004/003052A patent/AP2004003052A0/en unknown
- 2002-11-19 EP EP02795653A patent/EP1448200A2/en not_active Withdrawn
- 2002-11-19 AU AU2002360403A patent/AU2002360403A1/en not_active Abandoned
- 2002-11-19 US US10/299,746 patent/US7338965B2/en not_active Expired - Fee Related
- 2002-11-19 KR KR1020047007631A patent/KR20050044533A/ko not_active Application Discontinuation
- 2002-11-19 GE GE5634A patent/GEP20074045B/en unknown
- 2002-11-19 OA OA1200400289A patent/OA12812A/en unknown
- 2002-11-19 IL IL16207902A patent/IL162079A0/xx unknown
- 2002-11-19 JP JP2003545624A patent/JP2005514362A/ja active Pending
- 2002-11-19 NZ NZ533158A patent/NZ533158A/en unknown
- 2002-11-19 BR BR0214295-3A patent/BR0214295A/pt not_active IP Right Cessation
- 2002-11-19 WO PCT/US2002/037037 patent/WO2003043987A2/en active Application Filing
- 2002-11-19 EA EA200400699A patent/EA200400699A1/ru unknown
- 2002-11-19 RS YU54204A patent/RS54204A/sr unknown
- 2002-11-19 CA CA002467749A patent/CA2467749A1/en not_active Abandoned
-
2004
- 2004-05-19 TN TNP2004000088A patent/TNSN04088A1/en unknown
- 2004-05-19 IS IS7271A patent/IS7271A/is unknown
- 2004-05-26 CO CO04048699A patent/CO5580743A2/es not_active Application Discontinuation
- 2004-06-16 HR HR20040550A patent/HRP20040550A2/xx not_active Application Discontinuation
- 2004-06-18 NO NO20042580A patent/NO20042580L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AP2004003052A0 (en) | 2004-06-30 |
| IL162079A0 (en) | 2005-11-20 |
| GEP20074045B (en) | 2007-02-26 |
| JP2005514362A (ja) | 2005-05-19 |
| US20040034031A1 (en) | 2004-02-19 |
| EP1448200A2 (en) | 2004-08-25 |
| OA12812A (en) | 2006-07-10 |
| EA200400699A1 (ru) | 2004-12-30 |
| BR0214295A (pt) | 2004-11-09 |
| AU2002360403A1 (en) | 2003-06-10 |
| KR20050044533A (ko) | 2005-05-12 |
| CO5580743A2 (es) | 2005-11-30 |
| WO2003043987A2 (en) | 2003-05-30 |
| CA2467749A1 (en) | 2003-05-30 |
| NZ533158A (en) | 2006-09-29 |
| IS7271A (is) | 2004-05-19 |
| WO2003043987A3 (en) | 2003-07-10 |
| TNSN04088A1 (en) | 2006-06-01 |
| RS54204A (en) | 2006-12-15 |
| US7338965B2 (en) | 2008-03-04 |
| MXPA04004772A (es) | 2005-06-06 |
| NO20042580L (no) | 2004-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20040550A2 (en) | 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines and piperazines | |
| ATE411985T1 (de) | Substituierte piperazine als modulatoren des melanocortinrezeptors | |
| DE60232276D1 (de) | Alpha-(n-sulfonamid)acetamidderivate als beta-amyloidinhibitoren | |
| BR9711119A (pt) | Antagonistas muscarínicos. | |
| PE20070531A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
| NO20062303L (no) | Pyrazinderivater og farmasoytisk anvendelse derav | |
| MEP27708A (en) | Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors | |
| DE69429527D1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
| ATE378043T1 (de) | Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha- synuclein fibril krankheiten | |
| ATE466581T1 (de) | Verbindungen auf pyrimidin-basis als gsk-3-hemmer | |
| NO20060768L (no) | 1-(2-amino-benzol)-piperazinderivater som glycinopptaks-inhibitorer for behandling av psykoser | |
| MXPA05002420A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos. | |
| DE602004028150D1 (de) | Aminopyrazolderivate als gsk-3-inhibitoren | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| DE122010000034I2 (de) | Substituierte thien-3-yl-sulfonylamino(thio)carbonyl-triazolin(thi)one | |
| ATE524181T1 (de) | Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen | |
| NO20011891D0 (no) | Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon | |
| GT200000034A (es) | Compuestos y procedimientos para el tratamiento de asma, alergia y trastornos inflamatorios. | |
| UY26458A1 (es) | 2- (3,5-bis-trifluorometil-fenil) -n - metil - n - (6-morfolin - 4 - yl -4- o- tolil - piridin -3 - yl) isobutiramida | |
| BRPI0418255A (pt) | derivados de piperazina e piperidina n-substituìdos | |
| NO20015247L (no) | Glysinspaltingssysteminhibitorer som potensielle antipsykotika | |
| DE60108626D1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer | |
| ATE251614T1 (de) | Piperazinderivate als neurokinin-antagonisten | |
| BG105710A (en) | 5ht1 antagonists for antidepressant therapy | |
| DE69610978D1 (de) | 4-substituierte-3-peptidyl-azetidin-2-on-derivate als cystein-proteinase inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20061106 Year of fee payment: 5 |
|
| A1OB | Publication of a patent application | ||
| OBST | Application withdrawn |